Showing 1-10 of about 19 articles.
Surface Oncology, Inc.
IL-27 is a key regulator of checkpoint protein expressionSRF388 believed to be the only anti-IL-27 targeted agent in late-preclinical developmentInvestigational New Drug (IND) submission for SRF388 ...
Surface Oncology, Inc.
- Expression of IL-27 shown to contribute to upregulation of PD-L1, LAG-3, CTLA-4, and TIGIT - Surface Oncology will submit an IND for SRF388, a first-in-class IL-27 antibody, in Q4 2019 CAMBRIDGE, ...
Surface Oncology, Inc.
CAMBRIDGE, Mass., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor ...
Surface Oncology, Inc.
CAMBRIDGE, Mass., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor ...
Surface Oncology, Inc.
Significantly reduces scope of its CD47 program, SRF231Accelerates IND filing for SRF388 (IL-27) into Q4 2019IND filing for SRF617 (CD39) remains on track for Q4 2019 CAMBRIDGE, Mass., Dec. 18, ...
Surface Oncology, Inc.
CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor ...
Surface Oncology, Inc.
CAMBRIDGE, Mass., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor ...
Surface Oncology, Inc.
CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor ...
Surface Oncology, Inc.
CAMBRIDGE, Mass., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor ...
Surface Oncology, Inc.
CAMBRIDGE, Mass., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor ...
Showing 1-10 of about 19 articles.
